Introduction {#S0001}
============

In the last decade, HIV testing services have been scaled-up substantially. In 2005, it was estimated that only 12% of people who wanted an HIV test were able to access testing; and that only 10% of people with HIV in Africa knew their status \[[1](#CIT0001)\]. In contrast, between 2010 and 2014, more than 600 million people in 122 low- and middle-income countries received HIV testing \[[2](#CIT0002)\], and as of 2015, approximately 60% of people with HIV were aware of their status \[[3](#CIT0003)\]. Such scale-up has been possible through the expansion of provider-initiated testing and counselling and community-based testing programmes, which have routinized HIV testing and extended services to many people.

Rapid diagnostic tests (RDTs) have been instrumental to the scale-up of HIV testing, particularly in resource-limited settings where access to laboratory services is poor. RDTs have been shown to be highly accurate and can often provide a same-day diagnosis when used within a validated testing strategy (i.e. the order in which the tests are performed) and algorithm (i.e. the exact tests used within the testing strategy) according to high (≥5%) and low HIV prevalence (\<5%), as recommended by the World Health Organization (WHO) \[[4](#CIT0004)--[6](#CIT0006)\]. Recent reports, however, have shown that HIV testing is not always conducted appropriately \[[7](#CIT0007),[8](#CIT0008)\], and in some countries, quality systems have not kept pace with testing scale-up. According to a review of national HIV testing policies, less than 20% of testing strategies were consistent with WHO guidance, and only two included recommendations on retesting prior to the initiation of antiretroviral therapy (ART) \[[9](#CIT0009)\]. In some cases, poor-quality testing has resulted in incorrect test results and the misdiagnosis of HIV status \[[10](#CIT0010)--[14](#CIT0014)\].

HIV misdiagnosis refers to any testing event where a diagnosis is missed, inappropriately delayed or incorrect (either false positive or false negative) \[[15](#CIT0015)\]. Poor-quality HIV testing and misdiagnosis have negative consequences for individuals, families, communities, health workers and health services. False negative diagnoses represent missed opportunities to identify an HIV infection and link people to early treatment. False positive diagnoses may cause social and emotional harm and create mistrust of health workers and the test results they deliver. Without addressing HIV testing quality, new guidance offering same-day treatment to all people diagnosed with HIV \[[16](#CIT0016)\] could lead to inappropriate ART initiation \[[11](#CIT0011)\]. Once individuals are on treatment, because ART reduces antibody production and can cause seroreversion, for example, false negative test results, determining a person's true HIV status can be especially challenging \[[17](#CIT0017),[18](#CIT0018)\].

We conducted this systematic review to assess the magnitude of misdiagnosis and to identify and describe poor HIV testing practices using RDTs, including those which may have led to incorrect test results and misdiagnosis.

Methods {#S0002}
=======

We systematically searched for peer-reviewed articles published from 1 January 1990 to 19 April 2017 using a predefined search strategy in the following electronic databases: PubMed, CINAHL and EMBASE. All conferences of the International AIDS Society were searched from July 2001 through July 2016; the most recent Conference on Retroviruses and Opportunistic Infections (2014--2017) database were searched because past conference abstracts were unavailable. Conferences of the African Society of Laboratory Medicine (ASLM) were searched 2012--2016, as well as the ASLM website and other key global health websites (see supplementary information). We searched reference lists to identify additional literature. This process was repeated until no new citations were identified. Experts were also contacted to identify additional reports. No geographic restrictions were placed on the search, but the review was limited to studies published in English.

Studies were eligible if they used at least two RDTs and reported on HIV misdiagnosis, factors related to potential misdiagnosis or described quality issues and related to HIV testing error.

Initial titles were screened by one investigator (VF) to determine eligibility. A second and a third screening was then carried out (VF, ST and CJ). All differences were resolved through consensus. Data from all sources were extracted and placed into standardized forms and verified in duplicate (VF and ST). CJ and NF assessed study quality (see supplementary data).

Potential factors relating to misdiagnosis were extracted from studies using defined categories: (a) clerical error (error in documenting and reporting information essential to a correct status); (b) user error (operator error collecting specimen, performing an HIV RDT or interpreting the result); (c) suboptimal testing strategy (errors related to the order in which specific RDTs are used, also known as a testing strategy); (d) poor management and supervision (lack of active quality management systems); (e) weak reactive results (faint lines appearing on test strips); and (f) additional factors including cross-reactivity, acute/early infection and testing among people on ART.

Other summary measures included: misdiagnosis rates (total number of false positive diagnoses reported over the total number of HIV-positive tests retested and reported using a specific testing algorithm and the total number of false negative diagnoses reported over the number of HIV-negative tests retested and reported using a specific testing algorithm). For studies exclusively among people diagnosed with HIV, reporting on false positive statuses, the total study population was used as the denominator.

For each study, rates of diagnostic error and misdiagnosis and corresponding 95% confidence intervals (CIs) were calculated, using Wilson's approach, and this was displayed graphically using forest plots \[[19](#CIT0019)--[21](#CIT0021)\]. All statistical analyses were conducted in STATA v13.0.

Results {#S0003}
=======

Sixty-four studies reporting on misdiagnosis of HIV and factors potentially related to misdiagnosis were included in this review ([Figure 1](#F0001) and [Table 1](#T0001)).Table 1.Classification of included studies (*n* = 64)CategoryStudyLocation**Potential HIV misdiagnosis and related factors**Aghokeng et al. \[[22](#CIT0022)\]CameroonBaltazar et al. \[[23](#CIT0023)\]MozambiqueBaveewo et al. \[[24](#CIT0024)\]UgandaBock et al. \[[14](#CIT0014)\]South Africa and ZambiaBoeras et al. \[[25](#CIT0025)\]Zambia and RwandaCDC \[[26](#CIT0026)\]Low- and low--middle-income countries (not specified)Crucitti et al. \[[27](#CIT0027)\]Benin, India, South Africa, Uganda and Indiada Costa et al. \[[28](#CIT0028)\]BrazilEller et al. \[[29](#CIT0029)\]UgandaFogel et al. \[[23](#CIT0023)\]Multiple countries in AfricaGaliwango et al. \[[30](#CIT0030)\]CameroonGranade et al. \[[31](#CIT0031)\]USAGray et al. \[[32](#CIT0032)\]UgandaHsiao et al. \[[33](#CIT0033)\]South AfricaJentsch et al. \[[34](#CIT0034)\]South Africa, Tanzania, Uganda and ZambiaKanal et al. \[[35](#CIT0035)\]CambodiaKarugaba et al. \[[36](#CIT0036)\]UgandaKhan et al. \[[37](#CIT0037)\]SwazilandKlarkowski et al. \[[38](#CIT0038)\]Central Africa Republic, Congo, DRC, Ethiopia, Haiti, India, Cote d'Ivoire, Myanmar, Uganda and ZimbabweKlarkowski et al. \[[10](#CIT0010)\]DRCKufa et al. \[[39](#CIT0039)\]South AfricaLearmonth et al. \[[40](#CIT0040)\]Multi-country study (26 countries)Manak et al. \[[16](#CIT0016)\]NigeriaMaparo et al. \[[41](#CIT0041)\]ZimbabweMartin et al. \[[42](#CIT0042)\]USAMasina et al. \[[43](#CIT0043)\]MalawiMayaphi et al. \[[44](#CIT0044)\]South AfricaMehra et al. \[[45](#CIT0045)\]IndiaMine et al. \[[46](#CIT0046)\]BotswanaNelson et al. \[[47](#CIT0047)\]MozambiqueSacks et al. \[[48](#CIT0048)\]UKShanks et al. \[[11](#CIT0011)\]DRC, Burundi and EthiopiaShanks et al. \[[13](#CIT0013)\]EthiopiaShanks et al. \[[12](#CIT0012)\]EthiopiaSimoncini et al. \[[49](#CIT0049)\]NigerStetler et al. \[[50](#CIT0050)\]HondurasTchounga et al. \[[51](#CIT0051)\]Burkina Faso, Cote d'Ivoire and MaliWolpaw et al. \[[52](#CIT0052)\]South AfricaViani et al. \[[53](#CIT0053)\]USA and MexicoYoung et al. \[[54](#CIT0054)\]Mozambique**Focus on misdiagnosis of HIV-negative serostatus**Bassett et al. \[[55](#CIT0055)\]South AfricaKahemele et al. \[[56](#CIT0056)\]TanzaniaMatambo et al. \[[57](#CIT0057)\]ZimbabweOlaru et al. \[[58](#CIT0058)\]Zimbabwe**General quality issues from sites conducting HIV testing services**Adebayo et al. \[[59](#CIT0059)\]NigeriaBenzaken et al. \[[60](#CIT0060)\]BrazilBile et al. \[[61](#CIT0061)\]BotswanaCham et al. \[[62](#CIT0062)\]30 countries in Africa**General quality issues**Iwe et al. \[[63](#CIT0063)\]Nigeria**from sites conducting**Kalou et al. \[[64](#CIT0064)\]Uganda and Tanzania**HIV testing services**Kitheka et al. \[[65](#CIT0065)\]Kenya*(Continued)*Kyaw et al. \[[8](#CIT0008)\]Myanmar Louis et al. \[[66](#CIT0066)\]Haiti Lali et al. \[[67](#CIT0067)\]Uganda Manyazewal et al. \[[68](#CIT0068)\]Ethiopia Mashauri et al. \[[69](#CIT0069)\]Tanzania Mwangala et al. \[[70](#CIT0070)\]Zambia Ntim et al. \[[71](#CIT0071)\]Ghana Ocheng et al. \[[72](#CIT0072)\]Tanzania Plate et al. \[[5](#CIT0005)\]11 countries in Africa SEAD \[[7](#CIT0007)\]South Africa Sushi et al. \[[73](#CIT0073)\]India Tegbaru et al. \[[74](#CIT0074)\]Ethiopia[^1] Figure 1.Study selection process.RDT: rapid diagnostic test; WB: Western blot; EIA: enzyme immunoassay.

Most studies were carried out in Africa (*n* = 48) \[[5](#CIT0005),[7](#CIT0007),[10](#CIT0010)--[14](#CIT0014),[16](#CIT0016),[22](#CIT0022)--[25](#CIT0025),[29](#CIT0029),[30](#CIT0030),[32](#CIT0032)--[34](#CIT0034),[36](#CIT0036),[37](#CIT0037),[39](#CIT0039),[41](#CIT0041),[43](#CIT0043),[44](#CIT0044),[46](#CIT0046),[47](#CIT0047),[49](#CIT0049),[51](#CIT0051),[52](#CIT0052),[54](#CIT0054)--[59](#CIT0059),[61](#CIT0061)--[65](#CIT0065),[67](#CIT0067)--[72](#CIT0072),[74](#CIT0074),[75](#CIT0075)\], followed by in the Americas (*n* = 7) \[[28](#CIT0028),[31](#CIT0031),[42](#CIT0042),[50](#CIT0050),[53](#CIT0053),[60](#CIT0060),[66](#CIT0066)\], Asia (*n* = 4) \[[8](#CIT0008),[35](#CIT0035),[45](#CIT0045),[73](#CIT0073)\] and Europe (*n* = 1) \[[48](#CIT0048)\]. There were also four multi-country/regional studies \[[26](#CIT0026),[27](#CIT0027),[38](#CIT0038),[40](#CIT0040)\]. Samples varied by size and unit of measurement, including clients (*n* = 38 studies, range: 303,010 to 1 clients), specimens (*n* = 15 studies, range: 9419 to 16 specimens), health workers performing HIV tests (*n* = 5 studies, range: 3835 to 39 personnel) and sites where HIV testing was performed (*n* = 12 studies, range: 602 to 4 sites). Nine studies reported more than one unit of measure, and three studies did not specify sample size (see supplementary information). The majority of studies occurred in a facility-based setting; studies carried out in community settings included the workplace (*n* = 1) \[[57](#CIT0057)\], home-based testing (*n* = 2) \[[14](#CIT0014),[39](#CIT0039)\] and a mobile setting (*n* = 1) \[[32](#CIT0032)\].

Factors related to the quality of HIV testing and potential misdiagnosis {#S0003-S2001}
------------------------------------------------------------------------

Several factors, including HIV testing errors, were reported frequently (*n* = 131 times) across all included studies (see [Table 2](#T0002)).Table 2.Reported HIV testing errors and factors potentially related to misdiagnosisCategoryNo. of StudiesIncorrect/suboptimal testing strategy or algorithm (e.g. testing strategies not aligned to the World Health Organizationrecommendations, such as a tiebreaker or parallel testing strategies, use of a single RDT to make an HIV-positivediagnosis)37User error (e.g. errors performing RDT or interpreting results, misapplication of buffer, inaccurate reading time and otherhuman errors)25Poor or inadequate management and supervision (e.g. work load stress, staff shortages, lack of training, poor adherenceto testing strategy or testing algorithm, substandard operating procedures, testing in window period)21Other factors (e.g. acute infection, cross-reactivity, known HIV status/on ART)18Clerical/technical errors (e.g. mislabelling, poor record-keeping and clerical mistakes)16Weak reactive test results (e.g. faint or ghost lines appearing on test strip)14[^2] Table 3.**Rates of false positive diagnosis rates among people diagnosed with HIV and/or enrolled in care or antiretroviral therapy (ART)**Study/authorSample sizeTotal no. of retestedNo. of false positivesPercentage of false positive diagnosesKlarkowski et al. 2009365229246.6Shanks et al. 2013c91454444.8Shanks et al. 2013b14914974.7Shanks et al. 2013a787822.6Khan et al. 2017253388140.55Hsiao et al. 20179523730.3Maparo et al. 20151447144740.28Nelson et al. 20163160314630.1

Thirty-seven studies reported using a suboptimal testing strategy that differed from the WHO recommendations \[[5](#CIT0005),[8](#CIT0008),[11](#CIT0011)--[14](#CIT0014),[16](#CIT0016),[22](#CIT0022)--[30](#CIT0030),[32](#CIT0032)--[34](#CIT0034),[36](#CIT0036)--[39](#CIT0039),[42](#CIT0042)--[44](#CIT0044),[49](#CIT0049),[51](#CIT0051),[53](#CIT0053),[59](#CIT0059),[62](#CIT0062),[64](#CIT0064)--[66](#CIT0066),[68](#CIT0068),[72](#CIT0072),[75](#CIT0075)\]. Suboptimal testing strategies included using a highly specific first-line test and highly sensitive second-line test \[[14](#CIT0014),[33](#CIT0033),[39](#CIT0039),[55](#CIT0055)\], using a single RDT for HIV-positive diagnoses \[[11](#CIT0011),[66](#CIT0066),[72](#CIT0072)\], using a high prevalence testing strategy in a low prevalence setting \[[16](#CIT0016),[49](#CIT0049)\], using a parallel testing algorithms and a tiebreaker testing strategy (where a third assay is used to resolve discrepant test results and rule in HIV infection) \[[5](#CIT0005),[12](#CIT0012),[13](#CIT0013),[16](#CIT0016),[24](#CIT0024),[25](#CIT0025),[27](#CIT0027)--[30](#CIT0030),[32](#CIT0032),[34](#CIT0034),[36](#CIT0036),[37](#CIT0037),[68](#CIT0068)\].

User errors, incorrectly performing the test procedure or incorrectly interpreting results, defined as human errors, were reported in 25 studies \[[7](#CIT0007),[8](#CIT0008),[11](#CIT0011),[14](#CIT0014),[26](#CIT0026)--[28](#CIT0028),[31](#CIT0031),[33](#CIT0033),[34](#CIT0034),[37](#CIT0037),[40](#CIT0040),[42](#CIT0042),[46](#CIT0046),[52](#CIT0052),[54](#CIT0054),[57](#CIT0057),[60](#CIT0060),[65](#CIT0065)--[68](#CIT0068),[70](#CIT0070),[72](#CIT0072),[73](#CIT0073)\]. Errors identified included users having difficulty with specimen collection \[[14](#CIT0014),[28](#CIT0028),[68](#CIT0068)\], performing RDTs \[[31](#CIT0031),[73](#CIT0073)\], interpreting test results \[[10](#CIT0010),[24](#CIT0024),[27](#CIT0027),[30](#CIT0030),[32](#CIT0032),[40](#CIT0040),[42](#CIT0042),[48](#CIT0048),[62](#CIT0062),[65](#CIT0065),[66](#CIT0066),[74](#CIT0074)\], reading test results too early \[[7](#CIT0007)\] and not using the correct reagents/buffer \[[7](#CIT0007)\].

Twenty-one studies reported inadequate management and supervision \[[7](#CIT0007),[8](#CIT0008),[11](#CIT0011),[26](#CIT0026),[27](#CIT0027),[31](#CIT0031),[41](#CIT0041),[43](#CIT0043),[46](#CIT0046),[52](#CIT0052),[59](#CIT0059),[62](#CIT0062),[64](#CIT0064)--[67](#CIT0067),[69](#CIT0069),[71](#CIT0071),[72](#CIT0072),[74](#CIT0074)\]. Of these, 10 studies reported issues with management of supplies \[[7](#CIT0007),[11](#CIT0011),[26](#CIT0026),[27](#CIT0027),[62](#CIT0062),[64](#CIT0064),[67](#CIT0067),[69](#CIT0069),[72](#CIT0072),[74](#CIT0074)\], including stock-outs \[[7](#CIT0007),[26](#CIT0026),[62](#CIT0062),[64](#CIT0064),[67](#CIT0067),[69](#CIT0069)\], the use of damaged or expired RDTs \[[26](#CIT0026),[27](#CIT0027),[64](#CIT0064),[67](#CIT0067)\] and inappropriate RDTs (i.e. syphilis RDTs) for HIV testing \[[72](#CIT0072)\]. Other factors related to poor management and supervision included testing within the window period without referring clients for retesting \[[32](#CIT0032),[45](#CIT0045)\], HIV testing performed by undertrained or ineligible staff \[[7](#CIT0007),[31](#CIT0031),[59](#CIT0059),[64](#CIT0064),[72](#CIT0072)\], low levels of retesting to verify diagnosis before ART initiation \[[43](#CIT0043)\], poor participation in external quality assessment (EQA) schemes \[[62](#CIT0062)\], poor site-level supervision \[[65](#CIT0065)\] and poor adherence to standard operating procedures \[[7](#CIT0007),[35](#CIT0035),[52](#CIT0052),[59](#CIT0059),[67](#CIT0067),[69](#CIT0069)\].

Sixteen studies reported clerical errors \[[8](#CIT0008),[11](#CIT0011),[26](#CIT0026),[28](#CIT0028),[29](#CIT0029),[31](#CIT0031),[34](#CIT0034),[35](#CIT0035),[45](#CIT0045),[50](#CIT0050),[63](#CIT0063)--[65](#CIT0065),[67](#CIT0067),[73](#CIT0073),[75](#CIT0075)\]. Errors included poor record-keeping \[[35](#CIT0035)\], data reporting problems, labelling and transcription mistakes \[[73](#CIT0073)\] and specimen mix-ups. Poor record-keeping, according to one study, resulted in nearly 30% of errors leading to incorrect status \[[67](#CIT0067)\]. Clerical errors were not always clearly defined and may not have always led to misdiagnosis \[[28](#CIT0028)\].

Fourteen studies reported challenges related to weak reactive test results, particularly difficulty with interpretation \[[8](#CIT0008),[10](#CIT0010),[24](#CIT0024),[27](#CIT0027),[30](#CIT0030),[32](#CIT0032),[36](#CIT0036),[38](#CIT0038),[40](#CIT0040),[42](#CIT0042),[44](#CIT0044),[48](#CIT0048),[62](#CIT0062),[74](#CIT0074)\]. A study, which assessed the proficiency of laboratory technicians, found that specimens with very weak levels of HIV-1/2 antibodies were less accurately reported \[[40](#CIT0040)\]. In Uganda, two studies found that the majority of false reactive results came from weak reactive RDTs \[[32](#CIT0032),[36](#CIT0036)\]. A study from the UK that assessed the visual depiction of false reactive and true positive readings reported that most false reactive specimens had a fainter test line than true positive specimens \[[48](#CIT0048)\]. Two studies reported incorrect reading of weak reactive bands contributed to the misdiagnosis \[[10](#CIT0010),[11](#CIT0011)\].

Eighteen studies reported on several other testing errors and factors potentially related to misdiagnosis. Nine of these studies reported cross-reactivity either between RDTs within an algorithm or with population and individual characteristics \[[10](#CIT0010),[22](#CIT0022),[24](#CIT0024),[25](#CIT0025),[27](#CIT0027),[32](#CIT0032),[38](#CIT0038),[56](#CIT0056),[60](#CIT0060)\]. One study suggested that cross-reactivity between assays used within an algorithm resulted in false positive statuses \[[27](#CIT0027)\]. Another hypothesized that cross-reactivity may present as weak reactive lines and thereby cause misdiagnosis \[[32](#CIT0032)\]. Six studies \[[10](#CIT0010),[11](#CIT0011),[25](#CIT0025),[38](#CIT0038),[56](#CIT0056),[60](#CIT0060)\] reported potential issues with RDTs interacting with characteristics of individuals undergoing testing \[[10](#CIT0010),[11](#CIT0011),[38](#CIT0038)\], including having low levels of HIV-1/2 antibodies due to late stage HIV infection \[[56](#CIT0056),[60](#CIT0060)\] and exposure of assays to adverse environmental conditions during storage and use \[[25](#CIT0025),[38](#CIT0038)\].

Additionally, six studies reported that a proportion of false negative diagnoses were among people with a known HIV status who were on ART \[[14](#CIT0014),[16](#CIT0016),[39](#CIT0039),[44](#CIT0044),[47](#CIT0047),[58](#CIT0058)\]; one of these studies was among children on ART retested using an oral fluid-based HIV RDT \[[58](#CIT0058)\]. And three studies reported false negative results were due to patients testing in the window period \[[45](#CIT0045)\] or with acute or early infection \[[16](#CIT0016),[44](#CIT0044)\]. For instance, in South Africa, 0.04% (95% CI: 0.0--0.001) and 0.3% (95% CI: 0.1--0.4) of clients with a false negative diagnosis using serology tests were later found to have acute or early HIV infection after retesting with nucleic acid testing technologies \[[44](#CIT0044)\].

False positive diagnostic errors and misdiagnosis rates {#S0003-S2002}
-------------------------------------------------------

Thirty studies reported on false positive diagnostic errors (43 reports; *n* = 16,777 total positive diagnoses). In general, error rates were small (median: 3.1%; IQR: 0.4%-5.2%) with the exception of a few studies where a tiebreaker test was used to resolve discrepant results \[[10](#CIT0010)--[14](#CIT0014),[23](#CIT0023),[32](#CIT0032),[33](#CIT0033),[37](#CIT0037),[39](#CIT0039),[41](#CIT0041),[44](#CIT0044),[46](#CIT0046),[47](#CIT0047),[75](#CIT0075)\] ([Figure 2](#F0002)). Of these, six studies (eight reports) exclusively among people with HIV enrolled in care or ART reported that between 0.1% (95% CI: 0--0.3) and 6.6% (95% CI: 4.5--9.6) of people were misdiagnosed (median: 1.6%, IQR: 0.3--4.7%) \[[10](#CIT0010)--[13](#CIT0013),[33](#CIT0033),[37](#CIT0037),[39](#CIT0039),[41](#CIT0041),[47](#CIT0047)\] ([Table 3](#T0003)).Figure 2.Rates of false positive diagnostic error rates diagnosis (*n* = 30 studies, 43 reports).LP: low prevalence; HP: high prevalence; ZAM: Zambia; VL: visceral Leishmaniasis; Data reported include reports of misdiagnosis of HIV-positive statuses. False positive diagnoses were reported in 30 studies (43 reports), total positive diagnoses *n* = 16,777. Kufa et al. 2017 reported proportion misdiagnosed by did not report full sample size. In studies where all participants were known to be HIV positive and/or on ART at the beginning of the study, the full study population was used as the denominator.

In studies reporting false positive diagnoses, nearly all reported the use of a suboptimal testing strategy \[[11](#CIT0011)--[13](#CIT0013),[33](#CIT0033),[39](#CIT0039),[49](#CIT0049),[75](#CIT0075)\]. Sixteen studies reported the use of a tiebreaker testing strategy were related to false positive HIV diagnoses \[[5](#CIT0005),[12](#CIT0012),[13](#CIT0013),[16](#CIT0016),[24](#CIT0024),[25](#CIT0025),[27](#CIT0027),[29](#CIT0029),[30](#CIT0030),[32](#CIT0032),[34](#CIT0034),[36](#CIT0036),[37](#CIT0037),[68](#CIT0068)\]. In one of these studies, 95% (123/129) of false positive statuses resulted specifically from using a tiebreaker test \[[32](#CIT0032)\]. Additionally, one study which reported misdiagnosis rates in Burundi, Democratic Republic of Congo (DRC) and Ethiopia reported some clients may have been provided an HIV-positive diagnosis based on a single HIV RDT \[[11](#CIT0011)\].

False negative diagnostic errors and misdiagnosis rates {#S0003-S2003}
-------------------------------------------------------

Twenty-eight studies reported on false negative diagnoses (40 reports, total negatives = 55,626) (median: 0.4%, IQR 0--3.9%) ([Figure 3](#F0003)) \[[10](#CIT0010),[12](#CIT0012),[13](#CIT0013),[37](#CIT0037),[39](#CIT0039),[47](#CIT0047),[55](#CIT0055)--[57](#CIT0057)\]. The studies reporting the highest proportions, for example, Olaru et al., which was designed to assess how ART impacts test performance \[[58](#CIT0058)\], of false negative diagnoses were exclusively among people with HIV on ART who were retested using an HIV RDT-based algorithm.Figure 3.**False** **negative diagnostic error rates (*n* = 28 studies, 40 reports).**LP: low prevalence; HP: high prevalence; SA: South Africa, discrepant results; ZAM: Zambia, discrepant results; VL: visceral Leishmaniasis; Data reported includes reports of misdiagnosis of HIV-negative statuses. Misdiagnoses of HIV-negative statuses were reported 28 studies (40 reports), total negative = 55, 626. Kufa et al. 2017 reported proportion misdiagnosed but did not report full sample size information.Note Olaru et al. was exclusively among people with HIV on ART, accounting for the high rate of false negative diagnoses.

Nearly all studies reporting false negative diagnoses also reported using a suboptimal testing strategy. Four studies in South Africa reporting false negative diagnoses reported that HIV testing was conducted with an algorithm using a first-line test with high specificity and poorer sensitivity \[[14](#CIT0014),[33](#CIT0033),[39](#CIT0039),[55](#CIT0055)\]. According to one of these studies \[[14](#CIT0014)\], between 2014 and 2016, the testing algorithm changed four times in an effort to address the high proportion of false negative diagnoses resulting from these algorithms.

Clerical and user errors \[[57](#CIT0057)\], early/acute infection \[[16](#CIT0016),[44](#CIT0044),[45](#CIT0045)\], presentation late in disease stage \[[56](#CIT0056)\] and individuals with known HIV status on ART who sought retesting, or were retested using oral fluid-based RDTs \[[58](#CIT0058)\], were also reported as factors contributing to false negative diagnostic errors \[[14](#CIT0014),[16](#CIT0016),[39](#CIT0039),[44](#CIT0044),[47](#CIT0047)\]. In Zimbabwe, all the reported false negative diagnoses were among children on ART who were retested with an oral fluid-based HIV RDT \[[58](#CIT0058)\]. In South Africa and Zambia, individuals on ART comprised 44% (26/59) and 14% (5/38) of false negative diagnoses, respectively \[[14](#CIT0014)\]. In Mozambique, 88% (21/24) of all true HIV-positive clients with a false negative test result were confirmed to know their HIV status and 62% (13/21) were reportedly on ART \[[47](#CIT0047)\]; reasons for retesting in study reportedly included users misunderstanding the question or hoping to receive health services and emotional or mental health issues.

Discussion {#S0004}
==========

This review identified and described a number of diagnostic errors and poor HIV testing practices that may lead to misdiagnosis. Data on the magnitude of misdiagnosis was identified but limited, and no study could determine or quantify the exact cause(s) of misdiagnosis. Although no studies could determine and quantify the exact cause(s) of misdiagnosis, several identified the following factors to have strongly contributed: (1) suboptimal testing strategies, (2) poor management of supplies, (3) user errors including difficulty interpreting weak reactive lines and (4) retesting among people with known HIV status on ART.

No assay is perfect. False reactive and false non-reactive results are inevitable when using a single RDT and should be anticipated. However, the risk of misdiagnosis should be very low when a validated testing algorithm for high (≥5%) or low (\<5%) prevalence settings is used \[[76](#CIT0076)\]. In this review, we identified that many studies reporting diagnostic errors - both false positive and false negative - utilized suboptimal testing strategies which were not aligned to international guidance. Studies reviewed clearly showed the use of a tiebreaker strategy to rule-in HIV infection increases the likelihood of false positive statuses and possible misdiagnosis. This is concerning because a third of national testing strategies reviewed in 2015 recommended using a tiebreaker testing strategy \[[9](#CIT0009)\].

In addition to adopting a proven testing strategy, national or regional validation is critical to determine which RDTs, and in which order, perform the best as a complete algorithm. As previously reported \[[38](#CIT0038),[77](#CIT0077)--[83](#CIT0083)\], tests and algorithm performance vary across settings, often due to cross-reactivity caused by HIV subtypes, co-infections, comorbidities and possible environmental or population characteristics. Without validating a testing algorithm at a country or regional level, it would not be possible to fully understand the causes of poor performance. Furthermore, to ensure correct diagnoses, it is important to retest people diagnosed HIV positive before they enrol in care and ART. This is a cost-effective approach \[[84](#CIT0084)\] which is increasingly critical as more people with HIV are being offered immediate treatment.

To ensure correct results, all staff providing HIV testing must be trained, certified and provided ongoing support and supervision. In several studies, this was not the case, and untrained and uncertified providers were performing HIV testing \[[7](#CIT0007),[72](#CIT0072)\]. Training, including pre-service, in-service and periodic refresher training, is important to maintain and improve the quality of services. Participation in EQA schemes is another way to monitor performance and improve testing services. Several studies also reported user and clerical errors resulted from inadequate support, demanding workloads, burnout and high levels of stress \[[11](#CIT0011),[62](#CIT0062),[64](#CIT0064),[66](#CIT0066)\]. Adequate support and supervision are critical to reduce stock outs which may contribute to the use of damaged or expired test kits, incorrect test kits and buffer. Sites should routinely assess and manage their supplies and human resource planning to prevent or reduce these circumstances.

User error interpreting weak reactive lines was a common challenge which contributed to false positive results. To address this, specialized training for health workers and site-level standard operating procedures including the use of a "second-reader" to validate the correct interpretation of test results may be needed, as well as work with manufacturers to improve RDTs and instructions on how to interpret faint lines and weak control lines. Several studies hypothesized that weak reactive lines may be caused by other user errors, for example, misapplication of buffer and reading test results too early and cross-reactivity. Further investigation into the cause of weak reactive and other faint lines, and how they can be prevented, is needed.

False negative test results among people with HIV and on ART were observed and contributed to a substantial proportion of misdiagnoses \[[14](#CIT0014),[16](#CIT0016),[39](#CIT0039),[44](#CIT0044),[47](#CIT0047)\]. While it is unclear why people on ART would seek retesting, some reports suggest it may be due to wanting to "check" or "confirm" one's HIV status and religious beliefs about being "cured" \[[85](#CIT0085)\], as well as misunderstandings and emotional or mental health issues \[[47](#CIT0047)\]. It is important for programmes and users to be aware of the potential risk of false negative results, as the presence of ART can lead to confusing test results and could result in individuals unnecessarily stopping treatment which could have dire individual and public health implications. As "treat all" policies are rolled out, it will be increasingly critical for programmes to address this issue and ensure clients and health workers are aware that testing individuals on ART is not recommended \[[76](#CIT0076)\].

Strengths and limitations {#S0005}
=========================

This analysis is the first to bring together a diverse set of studies with the aim of identifying and describing suboptimal HIV testing practices and misdiagnosis. The results indicate the problem of misdiagnosis deserves attention. However, there are several limitations to this review.

As with all literature reviews, publication bias may be an issue and for this topic is inevitable and information on misdiagnosis is often unreported. This review was also limited to reports in English and may have missed reports in other languages. The majority of reports are from Africa and may not be representative of other geographies. Because the review was designed to identify reports of misdiagnosis, it is possible studies reporting errors and quality of HIV testing may have been missed.

Due to both the paucity and heterogeneity of data, it was not possible to conduct more quantitative analyses. Studies included were generally not designed to determine the exact cause or causes of misdiagnoses, a weakness cited across research on diagnostic errors \[[86](#CIT0086)\].

This review focused on human errors and quality system failures. While we did identify some reports of cross-reactivity \[[10](#CIT0010),[22](#CIT0022),[24](#CIT0024),[25](#CIT0025),[27](#CIT0027),[32](#CIT0032),[38](#CIT0038),[56](#CIT0056),[60](#CIT0060)\], reports did not provide conclusive information on what exactly caused cross-reactivity. Possible biological factors due to antibodies from inter-current infections, adverse environmental exposure to assay components, HIV subtype or shared false cross-reactivity in RDTs within an algorithm may be issues requiring further investigation.

Acute and early infection did not appear to be a significant cause of false negative diagnoses; however, few studies identified reported on acute infection. Retesting among HIV-positive individuals taking ART did emerge as a key factor contributing to a substantial proportion of false negative diagnostic errors and misdiagnoses. Further research is needed to understand how ART, as well as the use of antiretroviral drugs for prevention, for example, pre-exposure prophylaxis, may impact the performance of HIV RDTs, as well as how frequently people previously diagnosed with HIV and on ART retest.

Conclusions {#S0006}
===========

Our review has identified a number of factors and practices that may contribute to diagnostic error and HIV misdiagnosis. Although no study could fully determine and quantify the exact cause(s) of misdiagnosis, our review elucidated four key factors: (1) suboptimal testing strategies, primarily the use of a tiebreaker testing strategy to rule in HIV infection, (2) user errors including interpretation of weak reactive lines, (3) inadequate management and supervision of testers and (4) retesting among people with HIV on ART. Most, if not all, are avoidable with appropriate guidelines, training and supervision. The consequences of misdiagnoses are serious at an individual and public health level. With the momentum to scale-up HIV diagnosis and linkage to ART, a parallel push to improve the quality of HIV testing services and prevent misdiagnosis is essential.
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[^1]: DRC: Democratic Republic of Congo.

[^2]: RDT: rapid diagnostic test; ART: antiretroviral therapy.

    Table includes 63 reporting studies. One study (Bile et al. 2017) did not report a specific factor or error related to misdiagnosis. Some studies reported multiple factors related to poor quality testing and factors that could be related to potential misdiagnosis.
